Vaxart, Inc. (NASDAQ:VXRT) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC increased its stake in Vaxart, Inc. (NASDAQ:VXRT) by 2.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,601,139 shares of the biotechnology company’s stock after acquiring an additional 57,911 shares during the quarter. Geode Capital Management LLC owned approximately 1.14% of Vaxart worth $1,723,000 at the end of the most recent reporting period.

Separately, Sequoia Financial Advisors LLC lifted its holdings in Vaxart by 140.9% in the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 35,213 shares during the last quarter. Hedge funds and other institutional investors own 18.05% of the company’s stock.

Wall Street Analyst Weigh In

Separately, B. Riley reduced their price target on shares of Vaxart from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th.

Vaxart Price Performance

Shares of NASDAQ:VXRT opened at $0.43 on Wednesday. The company’s fifty day moving average price is $0.44 and its 200 day moving average price is $0.61. The firm has a market capitalization of $97.03 million, a P/E ratio of -1.04 and a beta of 1.57. Vaxart, Inc. has a 12 month low of $0.29 and a 12 month high of $1.07.

Vaxart (NASDAQ:VXRT) last announced its quarterly earnings data on Thursday, March 20th. The biotechnology company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.05. The company had revenue of $15.19 million during the quarter, compared to the consensus estimate of $15.68 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. On average, sell-side analysts anticipate that Vaxart, Inc. will post -0.39 EPS for the current year.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.